TY - JOUR
T1 - A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration
T2 - A multicenter retrospective study
AU - Miyai, Takayuki
AU - Imai, Shungo
AU - Kashiwagi, Hitoshi
AU - Sato, Yuki
AU - Kadomura, Shota
AU - Yoshida, Kenji
AU - Yoshimura, Eri
AU - Teraya, Toshiaki
AU - Tsujimoto, Takashi
AU - Kawamoto, Yukari
AU - Itoh, Tatsuya
AU - Ueno, Hidefumi
AU - Goto, Yoshikazu
AU - Takekuma, Yoh
AU - Sugawara, Mitsuru
N1 - Funding Information:
Funding: This research was funded by JSPS KAKENHI, grant number JP19K23791.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12
Y1 - 2020/12
N2 - We previously constructed a risk prediction model of vancomycin (VCM)-associated nephrotoxicity for use when performing initial therapeutic drug monitoring (TDM), using decision tree analysis. However, we could not build a model to be used at the time of initial administration due to insufficient sample size. Therefore, we performed a multicenter study at four hospitals in Japan. We investigated patients who received VCM intravenously at a standard dose from the first day until the initial TDM from November 2011 to March 2019. Acute kidney injury (AKI) was defined according to the criteria established by the “Kidney disease: Improving global outcomes” group. We extracted potential risk factors that could be evaluated on the day of initial administration and constructed a flowchart using a chi-squared automatic interaction detection algorithm. Among 843 patients, 115 (13.6%) developed AKI. The flowchart comprised three splitting variables (concomitant drugs (vasopressor drugs and tazobactam/piperacillin) and body mass index ≥ 30) and four subgroups. The incidence rates of AKI ranged from 9.34 to 36.8%, and they were classified as low-, intermediate-, and high-risk groups. The accuracy of flowchart was judged appropriate (86.4%). We successfully constructed a simple flowchart predicting VCM-induced AKI to be used when starting VCM administration.
AB - We previously constructed a risk prediction model of vancomycin (VCM)-associated nephrotoxicity for use when performing initial therapeutic drug monitoring (TDM), using decision tree analysis. However, we could not build a model to be used at the time of initial administration due to insufficient sample size. Therefore, we performed a multicenter study at four hospitals in Japan. We investigated patients who received VCM intravenously at a standard dose from the first day until the initial TDM from November 2011 to March 2019. Acute kidney injury (AKI) was defined according to the criteria established by the “Kidney disease: Improving global outcomes” group. We extracted potential risk factors that could be evaluated on the day of initial administration and constructed a flowchart using a chi-squared automatic interaction detection algorithm. Among 843 patients, 115 (13.6%) developed AKI. The flowchart comprised three splitting variables (concomitant drugs (vasopressor drugs and tazobactam/piperacillin) and body mass index ≥ 30) and four subgroups. The incidence rates of AKI ranged from 9.34 to 36.8%, and they were classified as low-, intermediate-, and high-risk groups. The accuracy of flowchart was judged appropriate (86.4%). We successfully constructed a simple flowchart predicting VCM-induced AKI to be used when starting VCM administration.
KW - Acute kidney injury
KW - Decision tree analysis
KW - Therapeutic drug monitoring
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=85098227645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098227645&partnerID=8YFLogxK
U2 - 10.3390/antibiotics9120920
DO - 10.3390/antibiotics9120920
M3 - Article
AN - SCOPUS:85098227645
SN - 2079-6382
VL - 9
SP - 1
EP - 12
JO - Antibiotics
JF - Antibiotics
IS - 12
M1 - 920
ER -